Since patients often already have HF at primary presentation, and asymptomatic carriers are only treated after disease onset, we herein aimed to determine whether PLN-ASO administration has beneficial effects in a clinically relevant stage of advanced PLN-R14del cardiomyopathy. The gene discussed is PLN; the disease is cardiomyopathy.